Merrimack Pharma (MACK) – Analyst Ratings
-
Merrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 Disappoints
-
JPMorgan Downgrades Merrimack Pharmaceuticals (MACK) to Underweight
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MACK Stock Lookup